Resources

Dive into expert-led webinars, regulatory briefs, and GenAI insights designed to fast-track your drug development journey.

All Blogs

Webinar

Feb 28, 2025

Augmenting Regulatory Intelligence with AI

Webinar

Feb 28, 2025

Augmenting Regulatory Intelligence with AI

Webinar

Feb 28, 2025

Augmenting Regulatory Intelligence with AI

Webinar

Nov 20, 2024

Global Regulatory Strategy Webinar

Webinar

Nov 20, 2024

Global Regulatory Strategy Webinar

Webinar

Nov 20, 2024

Global Regulatory Strategy Webinar

Webinar

Sep 24, 2024

How to Charm the FDA in Six Meeting Types or Less

Webinar

Sep 24, 2024

How to Charm the FDA in Six Meeting Types or Less

Webinar

Sep 24, 2024

How to Charm the FDA in Six Meeting Types or Less

Webinar

Aug 28, 2024

Accelerating Pediatric Drug Development- The Role of Quantitative Clinical Pharmacology

Webinar

Aug 28, 2024

Accelerating Pediatric Drug Development- The Role of Quantitative Clinical Pharmacology

Webinar

Aug 28, 2024

Accelerating Pediatric Drug Development- The Role of Quantitative Clinical Pharmacology

Webinar

Jul 31, 2024

Pushing the 505 (b)(2) Envelope

Webinar

Jul 31, 2024

Pushing the 505 (b)(2) Envelope

Webinar

Jul 31, 2024

Pushing the 505 (b)(2) Envelope

Webinar

Jun 26, 2024

Regulatory Briefs: What's New in MIDD?

Webinar

Jun 26, 2024

Regulatory Briefs: What's New in MIDD?

Webinar

Jun 26, 2024

Regulatory Briefs: What's New in MIDD?

Newsroom

Jul 13, 2023

C-Path and Vivpro Formalize Partnership to Accelerate Drug Development

Newsroom

Jul 13, 2023

C-Path and Vivpro Formalize Partnership to Accelerate Drug Development

Newsroom

Jul 13, 2023

C-Path and Vivpro Formalize Partnership to Accelerate Drug Development

Webinar

Mar 29, 2023

Reimagining R&D Webinar Series presenting “Five Dos or Don’ts of Pre-IND Meetings”.

Webinar

Mar 29, 2023

Reimagining R&D Webinar Series presenting “Five Dos or Don’ts of Pre-IND Meetings”.

Webinar

Mar 29, 2023

Reimagining R&D Webinar Series presenting “Five Dos or Don’ts of Pre-IND Meetings”.

Webinar

Jan 12, 2023

Reimagining R&D Webinar Series presenting “Re-Imagining Drug Development with a Transformative Approach to Regulatory Submissions.”

Webinar

Jan 12, 2023

Reimagining R&D Webinar Series presenting “Re-Imagining Drug Development with a Transformative Approach to Regulatory Submissions.”

Webinar

Jan 12, 2023

Reimagining R&D Webinar Series presenting “Re-Imagining Drug Development with a Transformative Approach to Regulatory Submissions.”

Webinar

Nov 30, 2022

Reimagining R&D Webinar Series presenting “Role of a Clinical Pharmacologist in Setting Regulatory Strategy.”

Webinar

Nov 30, 2022

Reimagining R&D Webinar Series presenting “Role of a Clinical Pharmacologist in Setting Regulatory Strategy.”

Webinar

Nov 30, 2022

Reimagining R&D Webinar Series presenting “Role of a Clinical Pharmacologist in Setting Regulatory Strategy.”

Newsroom

Nov 18, 2022

Introducing Vivpro Varsity

Newsroom

Nov 18, 2022

Introducing Vivpro Varsity

Newsroom

Nov 18, 2022

Introducing Vivpro Varsity

Webinar

Oct 24, 2022

Reimagining R&D Webinar Series presenting “Project Optimus: Reimagining Oncology Drug Development with Dose Optimization”

Webinar

Oct 24, 2022

Reimagining R&D Webinar Series presenting “Project Optimus: Reimagining Oncology Drug Development with Dose Optimization”

Webinar

Oct 24, 2022

Reimagining R&D Webinar Series presenting “Project Optimus: Reimagining Oncology Drug Development with Dose Optimization”

Webinar

Sep 20, 2022

Reimagining R&D Webinar Series presenting “The Value and Role of Regulatory Intelligence in Pharma.”

Webinar

Sep 20, 2022

Reimagining R&D Webinar Series presenting “The Value and Role of Regulatory Intelligence in Pharma.”

Webinar

Sep 20, 2022

Reimagining R&D Webinar Series presenting “The Value and Role of Regulatory Intelligence in Pharma.”

Newsroom

Sep 11-13, 2022

Vivpro participates at RAPS Convergence, 2022

Newsroom

Sep 11-13, 2022

Vivpro participates at RAPS Convergence, 2022

Newsroom

Sep 11-13, 2022

Vivpro participates at RAPS Convergence, 2022

Webinar

Aug 22, 2022

Reimagining R&D Webinar Series presenting “How FDA and Payers utilize RWE: Similarities and Differences.”

Webinar

Aug 22, 2022

Reimagining R&D Webinar Series presenting “How FDA and Payers utilize RWE: Similarities and Differences.”

Webinar

Aug 22, 2022

Reimagining R&D Webinar Series presenting “How FDA and Payers utilize RWE: Similarities and Differences.”

Newsroom

Jul 11, 2022

Inaugural Webinar Session, Reimagining R&D Series presenting “Accelerating the Availability of Medication to Pediatric Patients.”

Newsroom

Jul 11, 2022

Inaugural Webinar Session, Reimagining R&D Series presenting “Accelerating the Availability of Medication to Pediatric Patients.”

Newsroom

Jul 11, 2022

Inaugural Webinar Session, Reimagining R&D Series presenting “Accelerating the Availability of Medication to Pediatric Patients.”

Newsroom

May 3-5, 2022

Vivpro participates at Bio-IT World Conference and Expo 2022

Newsroom

May 3-5, 2022

Vivpro participates at Bio-IT World Conference and Expo 2022

Newsroom

May 3-5, 2022

Vivpro participates at Bio-IT World Conference and Expo 2022

Newsroom

Jun 6, 2022

Vivpro announces participation in two major conferences for June 2022

Newsroom

Jun 6, 2022

Vivpro announces participation in two major conferences for June 2022

Newsroom

Jun 6, 2022

Vivpro announces participation in two major conferences for June 2022

Newsroom

Apr 6, 2022

Vivpro Announces New Executive Appointment: Dr. Pravin Jadhav, CEO

Newsroom

Apr 6, 2022

Vivpro Announces New Executive Appointment: Dr. Pravin Jadhav, CEO

Newsroom

Apr 6, 2022

Vivpro Announces New Executive Appointment: Dr. Pravin Jadhav, CEO

Newsroom

Sep 1, 2021

Join Vivpro at RAPS Convergence 2021

Newsroom

Sep 1, 2021

Join Vivpro at RAPS Convergence 2021

Newsroom

Sep 1, 2021

Join Vivpro at RAPS Convergence 2021

Newsroom

Jul 19, 2021

Vivpro Announces New Appointment To Board Of Advisors: Mr. Amit Kohli

Newsroom

Jul 19, 2021

Vivpro Announces New Appointment To Board Of Advisors: Mr. Amit Kohli

Newsroom

Jul 19, 2021

Vivpro Announces New Appointment To Board Of Advisors: Mr. Amit Kohli

Blog

Jul 13, 2021

There are six generics per branded oral product. Guess how many for Long-Acting Injectables (‘LAI’s)?- Less than 1 per branded product!

Blog

Jul 13, 2021

There are six generics per branded oral product. Guess how many for Long-Acting Injectables (‘LAI’s)?- Less than 1 per branded product!

Blog

Jul 13, 2021

There are six generics per branded oral product. Guess how many for Long-Acting Injectables (‘LAI’s)?- Less than 1 per branded product!

Newsroom

Jul 12, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Ajaz Hussain

Newsroom

Jul 12, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Ajaz Hussain

Newsroom

Jul 12, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Ajaz Hussain

Newsroom

Jul 6, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Katie Laessig

Newsroom

Jul 6, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Katie Laessig

Newsroom

Jul 6, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Katie Laessig

Newsroom

Jun 28, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Bev Incledon

Newsroom

Jun 28, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Bev Incledon

Newsroom

Jun 28, 2021

Vivpro Announces New Appointment To Board Of Advisors: Dr. Bev Incledon

Blog

Jun 1, 2021

R and D Intelligence in 5 Sec- 237 Original 505(b)(2) Approvals used Published Literature as Evidence for Approval

Blog

Jun 1, 2021

R and D Intelligence in 5 Sec- 237 Original 505(b)(2) Approvals used Published Literature as Evidence for Approval

Blog

Jun 1, 2021

R and D Intelligence in 5 Sec- 237 Original 505(b)(2) Approvals used Published Literature as Evidence for Approval

Blog

May 28, 2021

How Effective are Life-Cycle Management Strategies Across Top Pharmaceutical and Biotech Companies?

Blog

May 28, 2021

How Effective are Life-Cycle Management Strategies Across Top Pharmaceutical and Biotech Companies?

Blog

May 28, 2021

How Effective are Life-Cycle Management Strategies Across Top Pharmaceutical and Biotech Companies?

Blog

May 22, 2021

R and D Intelligence in 5 sec — What is the Value of Speed and Quality for Product Development?

Blog

May 22, 2021

R and D Intelligence in 5 sec — What is the Value of Speed and Quality for Product Development?

Blog

May 22, 2021

R and D Intelligence in 5 sec — What is the Value of Speed and Quality for Product Development?

Newsroom

Nov 10-13, 2022

Vivpro participates at the “Women of Color in Pharma” 6th Annual Conference

Newsroom

Nov 10-13, 2022

Vivpro participates at the “Women of Color in Pharma” 6th Annual Conference

Newsroom

Nov 10-13, 2022

Vivpro participates at the “Women of Color in Pharma” 6th Annual Conference

Blog

Oct 12, 2021

A Debate on Evidentiary Standards for Accelerated Approvals will Continue at the Oncologic Drugs Advisory Committee Meeting

Blog

Oct 12, 2021

A Debate on Evidentiary Standards for Accelerated Approvals will Continue at the Oncologic Drugs Advisory Committee Meeting

Blog

Oct 12, 2021

A Debate on Evidentiary Standards for Accelerated Approvals will Continue at the Oncologic Drugs Advisory Committee Meeting

Case Study

Jan 01, 2022

Has FDA issued a complete response after advisory committee meeting?

Case Study

Jan 01, 2022

Has FDA issued a complete response after advisory committee meeting?

Case Study

Jan 01, 2022

Has FDA issued a complete response after advisory committee meeting?

Case Study

Jan 01, 2022

RIA helped a Biotech company to develop a plan for immunogenicity assessment for new biologics licensing application (BLA) for Multiple Sclerosis treatment

Case Study

Jan 01, 2022

RIA helped a Biotech company to develop a plan for immunogenicity assessment for new biologics licensing application (BLA) for Multiple Sclerosis treatment

Case Study

Jan 01, 2022

RIA helped a Biotech company to develop a plan for immunogenicity assessment for new biologics licensing application (BLA) for Multiple Sclerosis treatment

Case Study

Jan 01, 2022

Has FDA required post-approval RCTs for orphan products in oncology approved based on single-arm studies?

Case Study

Jan 01, 2022

Has FDA required post-approval RCTs for orphan products in oncology approved based on single-arm studies?

Case Study

Jan 01, 2022

Has FDA required post-approval RCTs for orphan products in oncology approved based on single-arm studies?

Case Study

Jan 01, 2022

What Symbicort trials have pediatric patients enrolled down to Age 4, minimum?

Case Study

Jan 01, 2022

What Symbicort trials have pediatric patients enrolled down to Age 4, minimum?

Case Study

Jan 01, 2022

What Symbicort trials have pediatric patients enrolled down to Age 4, minimum?

Case Study

Jan 01, 2022

RIA helped a sponsor to design a new Phase 3 Clinical study with "Clinical Relapse" as outcome measures for the treatment of Multiple Sclerosis

Case Study

Jan 01, 2022

RIA helped a sponsor to design a new Phase 3 Clinical study with "Clinical Relapse" as outcome measures for the treatment of Multiple Sclerosis

Case Study

Jan 01, 2022